达肝素钠联合间苯三酚治疗子宫动脉血流异常型先兆流产研究

The study of daheparin sodium combined with phloroglucinol in the treatment of threatened abortion with abnormal uterine artery flow

目的研究达肝素钠联合间苯三酚治疗子宫动脉血流异常型先兆流产的有效性及安全性,为临床医师提供参考治疗方案。方法对2019年9月~2022年5月在潍坊医学院附属医院被诊断为子宫动脉血流异常型先兆流产的患者104例进行前瞻性研究。随机分为两组,对照组采用黄体酮+达肝素钠治疗,共计50例;实验组采用黄体酮+达肝素+间苯三酚治疗,共计54例。比较两组患者的治疗有效率、临床症状缓解率、不良反应发生率及妊娠结局情况。结果实验组治疗有效率为85.19%,对照组治疗有效率为66.00%,有统计学差异(P<0.05)。实验组治疗后子宫动脉RI、S/D水平均低于对照组(P<0.05)。两组阴道流血停止时间、肝肾功能、不良反应、妊娠结局、分娩方式、分娩出血量比较,差异无统计学意义(P>0.05)。结论达肝素钠联合间苯三酚可以降低子宫动脉RI、S/D水平,改善患者临床症状,提高保胎成功率,且不增加不良反应发生率。

Objective To study the efficacy and safety of daheparin sodium combined with phloroglucinol in the treatment of threatened abortion with abnormal uterine artery flow,and to provide reference treatment plan for clini⁃cians.Methods From September 2019 to May 2022,a prospective study was conducted on 104 patients diagnosed with abnormal uterine artery flow type threatened abortion in affiliated hospital of Weifang medical university.Patients were di⁃vided into the control group and the experimental group according to the random grouping principle.In the control group,a total of 50 cases were treated with progesterone combined with daheparin sodium.In the experimental group,a total of 54 cases were treated with progesterone combined with daheparin and phloroglucinol.The effective rate of treatment,re⁃mission rate of clinical symptoms,incidence of adverse reactions and pregnancy outcome were compared between the two groups.Results The effective rates were 85.19%in the experimental group and 66.00%in the control group,with statis⁃tical difference(P<0.05).The levels of uterine artery RI and S/D in experimental group were lower than those in control group after treatment(P<0.05).There were no significant differences in vaginal bleeding stop time,liver and kidney func⁃tion,adverse reactions,pregnancy outcome,delivery mode and delivery blood loss between two groups(P>0.05).Conclu⁃sion Daheparin sodium combined with phloroglucinol can reduce the level of uterine artery RI and S/D,improve the clinical symptoms of patients,improve the success rate of fetal protection,and will not increase the incidence of adverse reactions.